checkAd

    Die Story - geht weiter.... - 500 Beiträge pro Seite

    eröffnet am 01.09.10 14:25:48 von
    neuester Beitrag 21.12.10 12:06:36 von
    Beiträge: 5
    ID: 1.159.657
    Aufrufe heute: 0
    Gesamt: 390
    Aktive User: 0

    ISIN: US2777741057 · WKN: A1CUUH · Symbol: EAPH
    0,0000
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 25.04.24 Nasdaq OTC

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    10,000+25,00
    6,0000+25,00
    0,7113+21,90
    56,69+20,00
    0,6400+18,52
    WertpapierKursPerf. %
    0,7599-15,26
    9,7200-19,60
    4,0000-27,27
    2,7280-29,14
    14,510-32,32

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 01.09.10 14:25:48
      Beitrag Nr. 1 ()
      ;)

      Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team


      Lee Hendelson to Join Easton Pharmaceuticals, Public Company Experience Invaluable as New CFO
      TORONTO, Aug 30, 2010 (GlobeNewswire via COMTEX) -- Easton Pharmaceuticals (Pink Sheets:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products, announced today that Lee Hendelson has agreed to join the company as Chief Financial Officer. An Accountant, CFO and Controller for various companies during the past 35 years, Mr. Hendelson will provide direction for all financial matters for Easton Pharmaceuticals in his capacity as Chief Financial Officer.
      "As a public company, we are extremely pleased to have someone with Lee's solid experience as CFO," says John Easton, Easton Pharmaceuticals' Chairman of the Board. "He will help guide us through all the necessary regulatory filings and financial issues, and we will also be able to leverage many of Lee's proven skill-sets to move Easton Pharmaceuticals forward to success."

      Mr. Hendelson played an integral part in the financial management of, and preparation and filings of financial statements for various publicly traded companies, and worked closely with various venture capital firms in New York City and Palm Beach, Florida analyzing profitability for portfolio clients. Prior to joining Easton Pharmaceuticals, Mr. Hendelson built a successful accounting firm in the United States, providing specialized accounting services, tax problem resolution, tax preparation for businesses and estates, due diligence, forecasting and pro-forma financial statements for business plans. Mr. Hendelson attended The City University of New York and received his Bachelors of Science in Accounting.

      About Easton Pharmaceuticals Inc.

      Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products. The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment of FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product classified by the FDA as containing Generally Regarded as Safe substances and ingredients. For more information, visit http://www.eastonpharma.com

      Copyright (C)2010 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and, the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc. Other names and marks are the property of their respective owners.

      This highest-value, lowest cost press release is a service of So Act Network's Press Club. www.pressclub.biz

      This news release was distributed by GlobeNewswire, www.globenewswire.com

      SOURCE: Easton Pharmaeuticals


      By Staff

      CONTACT: CONTACT: Easton Pharmaceuticals Inc.
      Media relations:
      (416) 619-0291
      (347) 284-0192
      Fax: +1(888) 877-3723
      Media relations:
      Media@eastonpharma.com
      Investor relations:
      IR@eastonpharma.com
      info@eastonpharma.com
      www.eastonpharma.com

      (C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
      -0-

      INDUSTRY KEYWORD: Biotechnology
      SUBJECT CODE: PHARMACEUTICALS
      MANAGEMENT CHANGES
      Directors and Officers
      Avatar
      schrieb am 01.09.10 14:44:55
      Beitrag Nr. 2 ()
      Es gibt noch Einiges mehr:

      http://www.otcmarkets.com/stock/EAPH/news
      http://www.otcmarkets.com/stock/EAPH/financials


      wie z.B.:

      Quarterly Report Mar 31, 2010:
      http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…

      Quarterly Report Jun 30, 2010:
      http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…

      soviel zu ehem. Lampen, Lampi`s, LAM-Pharmaceuticals, etc.........:D

      !!! Sie und ihr Mythos lebt also doch weiter !!!

      stay and keep :cool:
      Avatar
      schrieb am 09.11.10 08:13:08
      Beitrag Nr. 3 ()
      Easton Pharmaceuticals Inc. (EAPH) - Financial and Strategic Analysis Review - new company profile released


      Es "bewegt" sich wieder etwas........

      http://www.pr-inside.com/easton-pharmaceuticals-inc-eaph-r22…

      ;)
      Avatar
      schrieb am 15.11.10 08:24:17
      Beitrag Nr. 4 ()
      Quarterly Report

      http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…


      "Totgesagte" leben länger ;)

      also, stay long and keep :cool:
      Avatar
      schrieb am 21.12.10 12:06:36
      Beitrag Nr. 5 ()
      Easton Pharmaceuticals Announces 2011 "Fast-to-Market" Plan To Introduce Products For Treating Female Sexual Arousal Disorders and Provide Alternative To Ineffective Hormonal Therapies


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      +1,61
      +0,71
      +0,53
      +0,88
      +1,32
      -2,44
      +1,52
      +0,71
      +0,21
      +2,56

      Meistdiskutiert

      WertpapierBeiträge
      228
      103
      99
      83
      70
      38
      35
      34
      33
      32
      Die Story - geht weiter....